medigraphic.com
Revista Médica Sinergia

2021, Number 12

<< Back

Revista Médica Sinergia 2021; 6 (12)

Wilson Disease: generalities and focus on a correlation study for the determination of serum ceruloplasmin between two methods for its diagnosis

Rojas MVJ, Pérez MJD, Padilla SLÁ

Language: Spanish
References: 26
Page:
PDF size: 250.30 Kb.


ABSTRACT

Wilson's disease is an autosomal recessive disorder of copper metabolism, causing cirrhosis of the liver and neuronal degeneration. A Pearson correlation study was carried out for 165 samples from the Immunology and Nephrology Divisions of the Clinical Laboratory of the San Juan de Dios Hospital, between the method considered as a reference, which is the enzymatic activity, and the serum concentration, which is the study method. They were segregated into three different groups according to the result obtained by the enzyme activity methodology and based on the reference values defined by this reference methodology in "values below the lower reference value", "values within the reference interval" and "values higher than the upper limit of reference ". A Pearson correlation study was performed for each group. It was evidenced that there is a poor correlation for the 4 settings, obtaining r = 0.84, r = 0.40, r = 0.44 and r = 0.74 respectively. It is recommended not to perform serum ceruloplasmin determinations based solely on the concentration of this protein carried out by immunoturbidimetry, especially in patients with suspected diagnosis of Wilson's disease. It was shown that there is a low correlation between the 2 available methodologies throughout their analytical range. The enzyme activity methodology is still considered the gold standard for the determination of this protein.


REFERENCES

  1. Ferenci P. Pathophysiology and Clinical Features. Metabolic Brain Disease. 2004;: p. 229-239.

  2. Moratorio I, Pontet Y, Hernández N. Enfermedad de Wilson: presentación hepática y revisión bibliográfica. Rev. urug. med. Interna. 2019 Mayo; 4(2).

  3. Ferenci P. Guías de Práctica Clínica de la EASL: Enfermedad de Wilson. Journal of Hepatology. 2012;: p. 671-685.

  4. Steindl P. Wilson’s disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology. 1997;: p. 212-218.

  5. Walshe J. Wilson’s disease: the importance of measuring serum caeruloplasmin non-immunologically. Ann Clin Biochem. 2003;: p. 115-121.

  6. Schosinsky K, Lehmann H, Beeler M. Measurement of Ceruloplasmin from its oxidase activity in serum by use of o-Dianisidine dihydrochloride. Clin.Chem. 1974;: p. 1556-1563.

  7. Schosinsky K, Vargas M, Esquivel A, Grant S, Artavia A, Chavarría M. Hallazgos de laboratorio en 61 casos de enfermedad de Wilson en Costa Rica. BINASSS. 1989;: p. 11-21.

  8. Urrutia H, Ileana A, Sanabria A, Sánchez M. National alliance for Wilson’s disease: health policy in Costa Rica. Hepatology, Medicine and Policy. 2017;: p. 1-6.

  9. Schilsky M. Wilson disease: Clinical manifestations, diagnosis, and natural history. Uptodate. [Online].; 2021 [cited 2021 Setiembre 11. Available from: https://www.uptodate.com/contents/wilson-disease-clinical-manifestations-diagnosis-and-natural-history.

  10. Feldman M, Friedman L, Brandt L. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Décima ed. Philadelphia: Elservier; 2016.

  11. Culotta V, Gitlin J. The Molecular and Metabolic Basis of Inherited Disease New York: McGraw-Hill; 2001.

  12. Migocka M. Copper-transporting ATPases: The evolutionarily conserved machineries for balancing copper in living systems. IUBMB Life. 2015 Octubre; 67(10).

  13. Sternlieb I. Perspectives on Wilson’s disease. Hepatology. 1990;: p. 1234-1239.

  14. Lutsenko S, Arnab G, Burkhead J, Zuzel V. Cellular multitasking: The dual role of human Cu-ATPases in cofactor delivery and intracellular copper balance. Elsevier. 2008 Agosto; 476(1).

  15. Hellman N, Gitlin J. Ceruloplasmin metabolism and function. Annu. Rev. Nutr. 2002;: p. 439-458.

  16. Lutsenko S, Barnes N, Bartee M, Dmitriev O. Function and Regulation of Human Copper-Transporting ATPases. Physiological Reviews. 2007 Julio; 87(3).

  17. Schilsky M. Wilson disease: Diagnostic tests. Uptodate. [Online].; 2021 [cited 2021 Setiembre 10. Available from: https://www.uptodate.com/contents/wilson-disease-diagnostic-tests.

  18. Herra S, Hevia F, Vargas M, Schosinsky M. Fulminant Wilson’s disease in Costa Rica. Clinico-pathological study of 7 cases. G E N. 1989;: p. 9-14.

  19. Clark Y. Enfermedad de Wilson. Actualidad del tema. Revista Médica Electrónica-SciELO. 2016 Febrero; 38(1).

  20. Gow P, R S, Angus P, A S, Wall A, R S. Diagnosis of Wilson’s disease: an experience over three decades. Gut. 2000;: p. 415-419.

  21. Aguilar M, González E, Perona J, Álvarez J. Ceruloplasmina y su importancia clínica como factor indicador del riesgo cardiovascular en una población de escolares de Granada. Nutr Hosp. 2011;: p. 655-658.

  22. Yapur V, Bustos M, González A, Negri G. Ceruloplasmina: determinación de su actividad ferroxidasa. Acta Bioquímica Clínica Latinoamericana. 2007;: p. 347-351.

  23. Perman J, Werlin S, Grand R, J W. Laboratory measures of copper metabolism in the differentiation of chronic active hepatitis and Wilson disease in children. J Pediatr. 1979;: p. 564-568.

  24. Korman J, Volenberg I, BJ, Webster J, Schiodt F, Squires JR. Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology. 2008;: p. 1167–1174.

  25. Merle U, Eisenbach C, Weiss K, Tuma S, Stremmel W. Serum ceruloplasmin oxidase activity is a sensitive and highly specific diagnostic marker for Wilson’s disease. J Hepatol. 2009;: p. 925-930.

  26. Macintyre G, S K, Gutfreund W, M W, Richard C, Diane C. Value of an enzymatic assay for the determination of. J Lab Clin Med. 2004;: p. 294-301.S




2020     |     www.medigraphic.com